Implementation of a mandatory donor RHD screening in Switzerland
| Autor: | Christoph Gassner, Beat M. Frey, Sofia Lejon Crottet, Behrouz Mansouri Taleghani, Christoph Niederhauser, Jochen Gottschalk, Stefano Fontana, Hein Hustinx, Christine Henny, Stefan Meyer, Peter Gowland, Kathrin Neuenschwander, Franziska Still, Martin Stolz |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Rh-Hr Blood-Group System Blood transfusion business.industry medicine.medical_treatment RhD positive Blood Donors Hematology Rhesus d Donor Selection Blood Grouping and Crossmatching Internal medicine RhD negative Humans Medicine Female 610 Medicine & health business Switzerland |
| Zdroj: | Transfusion and Apheresis Science. 50:169-174 |
| ISSN: | 1473-0502 |
| Popis: | Starting in 2013, blood donors must be tested at least using: (1) one monoclonal anti-D and one anti-CDE (alternatively full RhCcEe phenotyping), and (2) all RhD negative donors must be tested for RHD exons 5 and 10 plus one further exonic, or intronic RHD specificity, according to the guidelines of the Blood Transfusion Service of the Swiss Red Cross (BTS SRC). In 2012 an adequate stock of RHD screened donors was built. Of all 25,370 RhD negative Swiss donors tested in 2012, 20,015 tested at BTS Berne and 5355 at BTS Zürich, showed 120 (0.47%) RHD positivity. Thirty-seven (0.15%) had to be redefined as RhD positive. Routine molecular RHD screening is reliable, rapid and cost-effective and provides safer RBC units in Switzerland. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect